<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365437">
  <stage>Registered</stage>
  <submitdate>7/07/2014</submitdate>
  <approvaldate>8/08/2014</approvaldate>
  <actrnumber>ACTRN12614000849695</actrnumber>
  <trial_identification>
    <studytitle>Diagnostic and Prognostic Significance of Serum "Neutrophil Gelatinase-Associated Lipocalin" in Patients with Colorectal Cancer</studytitle>
    <scientifictitle>Diagnostic and Prognostic Significance of Serum "Neutrophil Gelatinase-Associated Lipocalin" in Patients with Colorectal Cancer</scientifictitle>
    <utrn>U1111-1151-1580</utrn>
    <trialacronym>CRC-NGAL</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>colon cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Colon cancer screening;
Studies on tissue samples have shown that NGAL expression increases in CRCs and inflammatory bowel diseases. This study is planned to investigate the usability of serum NGAL level as a diagnostic and/or prognostic biomarker, in patients with colorectal cancer. NGAL level was determined through serum samples. Blood was taken from each patient only once, before polypectomy (for the polip group) or surgery (for the cancer group).</interventions>
    <comparator>Standard treatment for colorectal cancer patients (Curative resection). Control group consist of healty individuals, so any treatment didn't aplly to them. Only blood samples were taken.</comparator>
    <control>Active</control>
    <interventioncode>Early detection / Screening</interventioncode>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Diagnostic role of serum NGAL levels on colorectal cancer patients assessed with using Human NGAL/Lipocalin-2 ELISA kit. All colorectal cancer patients serum NGAL levels determined and compared with the other groups (benign colon polyps and healthy individual).</outcome>
      <timepoint>12 months after reciept of all blood samples.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prognostic role of serum NGAL levels on colorectal cancer patients assessed with using Human NGAL/Lipocalin-2 ELISA kit. NGAL levels statistically evaluated according to the tumor diameter and amount of metastatic lymph nodes in patients with colorectal cancer.</outcome>
      <timepoint>12 months after reciept of all samples</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with colorectal carsinoma
Patients with colorectal polyps without carcinoma
Control group (patients whose colonoscopy examinations revealed no pathology named as control group)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active infection
Renal failure
Other organs cancer
Detection of less than 12 lymph nodes
Patients treated with neoadjuvant  chemotherapy
Blood samples with hemolysis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2011</anticipatedstartdate>
    <actualstartdate>12/09/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/09/2012</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Goztepe Education and Research Hospital</primarysponsorname>
    <primarysponsoraddress>Goztepe Education and Research Hospital 
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>TCSB Goztepe Education and Research Hospital
</fundingname>
      <fundingaddress>TCSB Goztepe Education and Research Hospital, 
Department of General Surgery
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to investigate the usability of serum neutrophil gelatinase-associated lipocalin (NGAL) level as a diagnostic and/or prognostic biomarker, in patients with colorectal cancer (CRC) or precancerous lesion.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>TCSB Goztepe Education and Research Hospital Ethics Committee</ethicname>
      <ethicaddress>TCSB Goztepe Education and Research Hospital, kadikoy, Istanbul
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</ethicaddress>
      <ethicapprovaldate>3/01/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Ibrahim Ali Ozemir</name>
      <address>Goztepe Education and Research Hospital
Department of General Surgery,
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</address>
      <phone>+905058032125</phone>
      <fax />
      <email>draliozemir@hotmail.com</email>
      <country>Turkey</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ibrahim Ali Ozemir</name>
      <address>Goztepe Education and Research Hospital
Department of General Surgery,
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</address>
      <phone>+905058032125</phone>
      <fax />
      <email>draliozemir@hotmail.com</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ibrahim Ali Ozemir</name>
      <address>Goztepe Education and Research Hospital
Department of General Surgery,
Doktor Erkin Street, Kadikoy, Istanbul, Turkey
Postcode:34722</address>
      <phone>+905058032125</phone>
      <fax />
      <email>draliozemir@hotmail.com</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ibrahim Ali Ozemir</name>
      <address>Kucuksu mah, Asma sok, Eston Kandilli Evleri, A12 blok, D:8, Kandilli, Uskudar, Istanbul</address>
      <phone />
      <fax />
      <email />
      <country>Turkey</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>